1417 related articles for article (PubMed ID: 31924756)
1. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.
Sheahan TP; Sims AC; Leist SR; Schäfer A; Won J; Brown AJ; Montgomery SA; Hogg A; Babusis D; Clarke MO; Spahn JE; Bauer L; Sellers S; Porter D; Feng JY; Cihlar T; Jordan R; Denison MR; Baric RS
Nat Commun; 2020 Jan; 11(1):222. PubMed ID: 31924756
[TBL] [Abstract][Full Text] [Related]
2. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial.
Arabi YM; Alothman A; Balkhy HH; Al-Dawood A; AlJohani S; Al Harbi S; Kojan S; Al Jeraisy M; Deeb AM; Assiri AM; Al-Hameed F; AlSaedi A; Mandourah Y; Almekhlafi GA; Sherbeeni NM; Elzein FE; Memon J; Taha Y; Almotairi A; Maghrabi KA; Qushmaq I; Al Bshabshe A; Kharaba A; Shalhoub S; Jose J; Fowler RA; Hayden FG; Hussein MA;
Trials; 2018 Jan; 19(1):81. PubMed ID: 29382391
[TBL] [Abstract][Full Text] [Related]
4. Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset.
Chan JF; Yao Y; Yeung ML; Deng W; Bao L; Jia L; Li F; Xiao C; Gao H; Yu P; Cai JP; Chu H; Zhou J; Chen H; Qin C; Yuen KY
J Infect Dis; 2015 Dec; 212(12):1904-13. PubMed ID: 26198719
[TBL] [Abstract][Full Text] [Related]
5. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Uzunova K; Filipova E; Pavlova V; Vekov T
Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
[TBL] [Abstract][Full Text] [Related]
6. A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV).
Momattin H; Al-Ali AY; Al-Tawfiq JA
Travel Med Infect Dis; 2019; 30():9-18. PubMed ID: 31252170
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.
de Wit E; Feldmann F; Cronin J; Jordan R; Okumura A; Thomas T; Scott D; Cihlar T; Feldmann H
Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6771-6776. PubMed ID: 32054787
[TBL] [Abstract][Full Text] [Related]
8. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial.
Arabi YM; Asiri AY; Assiri AM; Aziz Jokhdar HA; Alothman A; Balkhy HH; AlJohani S; Al Harbi S; Kojan S; Al Jeraisy M; Deeb AM; Memish ZA; Ghazal S; Al Faraj S; Al-Hameed F; AlSaedi A; Mandourah Y; Al Mekhlafi GA; Sherbeeni NM; Elzein FE; Almotairi A; Al Bshabshe A; Kharaba A; Jose J; Al Harthy A; Al Sulaiman M; Mady A; Fowler RA; Hayden FG; Al-Dawood A; Abdelzaher M; Bajhmom W; Hussein MA;
Trials; 2020 Jan; 21(1):8. PubMed ID: 31900204
[TBL] [Abstract][Full Text] [Related]
10. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
Vargas M; Servillo G; Einav S
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8592-8605. PubMed ID: 32894567
[TBL] [Abstract][Full Text] [Related]
11. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Martinez MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
[TBL] [Abstract][Full Text] [Related]
12. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
Yao TT; Qian JD; Zhu WY; Wang Y; Wang GQ
J Med Virol; 2020 Jun; 92(6):556-563. PubMed ID: 32104907
[TBL] [Abstract][Full Text] [Related]
13. A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.
Atzrodt CL; Maknojia I; McCarthy RDP; Oldfield TM; Po J; Ta KTL; Stepp HE; Clements TP
FEBS J; 2020 Sep; 287(17):3633-3650. PubMed ID: 32446285
[TBL] [Abstract][Full Text] [Related]
14. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.
Williamson BN; Feldmann F; Schwarz B; Meade-White K; Porter DP; Schulz J; van Doremalen N; Leighton I; Yinda CK; Pérez-Pérez L; Okumura A; Lovaglio J; Hanley PW; Saturday G; Bosio CM; Anzick S; Barbian K; Cihlar T; Martens C; Scott DP; Munster VJ; de Wit E
Nature; 2020 Sep; 585(7824):273-276. PubMed ID: 32516797
[TBL] [Abstract][Full Text] [Related]
15. An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.
Wang D; Li Z; Liu Y
J Infect Public Health; 2020 Oct; 13(10):1405-1414. PubMed ID: 32684351
[TBL] [Abstract][Full Text] [Related]
16. Treatment of SARS-CoV-2: How far have we reached?
Ahsan W; Javed S; Bratty MA; Alhazmi HA; Najmi A
Drug Discov Ther; 2020 May; 14(2):67-72. PubMed ID: 32336723
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19.
Wu L; Zheng Y; Liu J; Luo R; Wu D; Xu P; Wu D; Li X
Aging (Albany NY); 2021 Apr; 13(8):10833-10852. PubMed ID: 33879634
[TBL] [Abstract][Full Text] [Related]
18. [From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic].
Estella Á; Garnacho-Montero J
Med Intensiva (Engl Ed); 2020 Nov; 44(8):509-512. PubMed ID: 32423569
[No Abstract] [Full Text] [Related]
19. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.
Gordon CJ; Tchesnokov EP; Feng JY; Porter DP; Götte M
J Biol Chem; 2020 Apr; 295(15):4773-4779. PubMed ID: 32094225
[TBL] [Abstract][Full Text] [Related]
20. Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir.
Yin G; Zhang C; Jin H
JMIR Public Health Surveill; 2020 Jul; 6(3):e19538. PubMed ID: 32589146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]